Nitroxide-Modified NSAIDs Reduce Gut Toxicity and Thrombosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for conditions like arthritis and cancer is limited by their side effects, such as gut toxicity and thrombosis, necessitating the development of NSAIDs with reduced toxicity and antioxidant properties.
Innovation Solution
Development of compounds comprising NSAID moieties combined with nitroxide moieties, which are redox modified to provide antioxidant properties and reduce gut toxicity and thrombosis, while maintaining anticancer activity and superoxide dismutase mimetic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NSAIDs are taken chronically for extended periods to treat arthritis and cancer, then anticancer activity and anti-inflammatory effects are improved, but gut toxicity and thrombosis increase
Solution Approach 1:
The patent combines NSAID moieties with nitroxide moieties to create hybrid compounds that simultaneously provide anti-inflammatory/anticancer effects and antioxidant protection. The nitroxide group (e.g., TEMPO, TEMPOL) is chemically linked to the NSAID structure, allowing the compound to exert both COX inhibition and free radical scavenging activities, thereby reducing gut toxicity while maintaining anticancer efficacy
Solution Approach 2:
The invention creates composite molecular structures by conjugating nitroxide radicals with NSAID molecules. These composite compounds exhibit synergistic effects where the nitroxide component provides antioxidant activity that protects against oxidative stress-induced gut damage, while the NSAID component maintains anti-inflammatory and anticancer properties
2Reliability
If NSAIDs are taken chronically for extended periods to treat arthritis and cancer, then anticancer activity and anti-inflammatory effects are improved, but thrombosis risk increases
Solution Approach 1:
The patent merges nitroxide moieties with NSAID structures to create compounds that simultaneously provide anti-thrombotic protection. The nitroxide group acts as a free radical scavenger that prevents platelet aggregation and reduces thrombus formation, while the NSAID portion maintains cancer-fighting activity, thereby reducing thrombosis risk without compromising anticancer efficacy
Solution Approach 2:
The nitroxide moiety acts as an intermediary protective element between the NSAID and the body's harmful processes. It mediates the interaction by scavenging free radicals that would otherwise promote thrombus formation and oxidative stress, thereby reducing thrombosis risk while allowing the NSAID to continue exerting its anticancer effects
3Object-affected harmful factors
If nitroxide moieties are added to NSAIDs to reduce toxicity, then antioxidant properties and reduced gut toxicity are improved, but compound complexity increases
Solution Approach 1:
The patent segments the compound into distinct functional moieties: the nitroxide group (e.g., TEMPO, TEMPOL) and the NSAID group (e.g., aspirin, indomethacin, celecoxib). This segmentation allows each component to perform its specific function independently while being linked through a chemical bond, making the overall structure more manageable and easier to synthesize despite the added complexity
Solution Approach 2:
The nitroxide moiety serves multiple functions: it acts as a free radical scavenger, an antioxidant, and a stabilizing group for the NSAID molecule. This multi-functionality justifies the added structural complexity, as a single group provides multiple protective effects against oxidative stress and gut damage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate reduced gut toxicity and thrombosis, enhanced antioxidant effects, and effective anticancer activity, as shown by their ability to scavenge superoxide and inhibit prostaglandin and leukotriene production, thereby addressing the limitations of existing NSAIDs.
Implementation Method 1
the compounds of the invention are redox modified NSAIDs having anticancer activity and superoxide dismutase (SOD) mimetic activity
Implementation Method 2
the compounds of the invention are redox modified NSAIDs having anticancer activity and superoxide dismutase (SOD) mimetic activity
Data Source
AI summary
Disclosed are nitroxide modified NSAID compounds of the formula (I) or a pharmaceutically acceptable salt or enantiomer thereof:in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and n are defined herein and pharmaceutical compositions thereof. Further disclosed is a method of treating or preventing various disorders, such as inflammation, cancer, diabetes, a cardiovascular disorder, weight gain, polyps, and/or chronic pain, in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt or enantiomer of formula (I). A method of imaging the compound or pharmaceutically acceptable salt or enantiomer of formula (I) in the body of the animal is also provided.